MOA Object Clause amended and expanded through postal ballot
ACCPL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.3 pts less than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Accretion Pharma shareholders approved an amendment to the Object Clause of the company's Memorandum of Association via postal ballot. Notice dated September 1, 2026; resolution passed on October 9, 2026 (last day of e-voting). The change revises the Main Object Clause III(A) and adds 38 new sub-clauses under Clause III(B), numbered III(B)(10) to III(B)(47). These widen the company's authorized scope to include pharmaceuticals, healthcare services, food and nutraceuticals, research, investments, and other ancillary activities.
Broadens the range of businesses the company may lawfully undertake, enabling future diversification. No immediate financial impact on shareholders.